Treatment News : New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » September 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

September 23, 2013

New Tenofovir Has Lower Dose, Is Kinder to Kidneys and Bones

A new formulation of the widely used HIV antiretroviral tenofovir is potent at a lower dose and works as well as the current version of the drug—but it has fewer effects on indicators of kidney and bone health, aidsmap reports. Paul Edward Sax, MD, clinical director at Brigham and Women’s Hospital and a professor of medicine at Harvard Medical School, presented findings from a Phase II study comparing Gilead Sciences’ new tenofovir alafenamide (TAF) with tenofovir disoproxil fumarate (TDF), which is the sole ingredient in Viread and a component of the single-pill combination therapies Truvada, Atripla, Complera and Stribild.

Researchers have found that concentrations of TAF in HIV-infected cells are five times higher than those of TDF. The new formulation’s levels in blood are far lower by comparison, which would likely make TAF less toxic to the kidneys and bones.

In a double-blind, placebo-controlled study, the researchers divided 170 treatment naive people with HIV into groups with a ratio of two to one receiving either 10 milligrams of TAF or 300 mg of TDF once a day in a coformulated pill with elvitegravir, cobicistat and emtricitabine (which in the TDF arm meant the participants were taking Stribild) for 48 weeks.

At the study’s outset, the median viral load was about 40,000 and the median CD4 cell level was approximately 390. The participants had normal kidney function.

At the end of the 48 weeks, 88.4 percent of those taking the TAF coformulation had achieved an undetectable viral load, compared with 87.9 percent in the TDF group. Average CD4 gains between the two groups were a respective 177 and 204. None of these differences between the arms were statistically significant, meaning they could have happened by chance.

Indicators of kidney function, such as changes in a marker known as eGFR, evidence of protein in the urine and a shift in serum creatinine, suggested TAF is a safer drug. Similarly, indications of bone health, including DEXA scans taken at the spine and hip at 24 and 48 weeks to measure bone mineral density, showed less deterioration in the TAF group than in the TDF arm. A third of those taking TAF had no change in their hip bone density compared with 7 percent of the TDF group.

To read the aidsmap story, click here.

To read the conference abstract, click here.

Search: Tenofovir alafenamide, TAF, tenofovir disoproxil fumarate, TDF, Viread, Truvada, Atripla, Complera, Eviplera, Stribild, Paul Edward Sax, elvitegravir, emtricitabine, kidney function, bone function


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    koffeeboss
    Tucson
    Arizona


    cortaza100
    Chicago
    Illinois


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.